Results 201 to 210 of about 295,608 (311)

Interstitial Lung Disease in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A European Multicenter Study

Arthritis &Rheumatology, EarlyView.
Objective Interstitial lung disease (ILD) can occur in association with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV‐ILD) or as an isolated entity with positive ANCA (ANCA‐ILD). However, data on the epidemiology and outcomes of these conditions remain limited.
Aglaia Chalkia, Marusa Kotnik, Timothy J. Sadler, Spyridon Katechis, Rachel Jones, Ajay Kamath, Aladdin J. Mohammad, Sara Monti, Chetan Mukhtyar, Viral Nanda, Ioannis Petrakis, Dimitrios Petras, Ashnish Sinha, Pasupathy Sivasothy, Rona Smith, Kostas Stylianou, Dimitrios Vassilopoulos, Judith Babar, David Jayne   +18 more
wiley   +1 more source

Case Report: Secukinumab Experience in a Patient With Coexistence of Systemic Lupus Erythematosus, Ankylosing Spondylitis, and Antiphospholipid Antibody Syndrome. [PDF]

Case Rep Rheumatol
Basaran E, Bayrak BY, Karadag DT, Yazici A, Cefle A.   +4 more
europepmc   +1 more source

Lupus Disseminatus [PDF]

Proceedings of the Royal Society of Medicine, 1927
openaire   +2 more sources

Serum Proteomic Signatures of Rheumatoid Arthritis Risk and Response: Analysis of a Rheumatoid Arthritis Interception Trial

Arthritis &Rheumatology, EarlyView.
Objective Our study objective was to identify serum protein signatures associated with progression to rheumatoid arthritis (RA) and response to abatacept in at‐risk individuals. Methods A total of 440 serum samples from 118 APIPPRA (Arthritis Prevention In the Preclinical Phase of RA with Abatacept) study participants were selected from baseline to RA ...
Marianna Jasenecova, Carl Coyle, Alina Mihalovits, Sarah Ryan, Elizabeth Pook, Esperanza Perucha, Gabrielle Harker, Melody Chin, Sam Norton, Andrew P. Cope   +9 more
wiley   +1 more source

Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data. [PDF]

Lupus Sci Med
Lin A, Kandane-Rathnayake R, Morand EF, Connelly K.   +3 more
europepmc   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

Arthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava, Michelle Petri, Patrick G. Gavin, Eszter Csomor, Philip Z. Brohawn, Daniel Muthas, Adam Platt, Catharina Lindholm, Nicola Ferrari   +8 more
wiley   +1 more source

Beyond renal response: sustained systemic disease control protects against adverse long-term outcomes in lupus nephritis. [PDF]

Lupus Sci Med
Drougkas K, Katechis S, Kostopoulou M, Tsalapaki C, Flouda S, Pappa M, Bakula M, Padjen I, Nikoloudaki M, Konstantopoulou P, Moustakas G, Vassilopoulos D, Bertsias G, Voulgari PV, Boumpas DT, Fanouriakis A.   +15 more
europepmc   +1 more source

Lupus nephritis [PDF]

Nephrology Dialysis Transplantation, 2001
openaire   +2 more sources

Clinical Images: Subcutaneous panniculitis‐like T cell lymphoma

Arthritis &Rheumatology, EarlyView.
S Chambers, CN Myrdal, VP Werth
wiley   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source